NextCure Inc (NASDAQ:NXTC) was the target of a large drop in short interest during the month of November. As of November 29th, there was short interest totalling 506,800 shares, a drop of 19.0% from the November 14th total of 625,500 shares. Currently, 4.1% of the shares of the company are short sold. Based on an average trading volume of 477,000 shares, the days-to-cover ratio is presently 1.1 days.
In other NextCure news, major shareholder Sofinnova Venture Partners Ix, purchased 150,000 shares of the company’s stock in a transaction dated Friday, November 15th. The shares were acquired at an average price of $36.75 per share, for a total transaction of $5,512,500.00. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink.
A number of hedge funds have recently made changes to their positions in NXTC. Victory Capital Management Inc. purchased a new stake in NextCure in the 2nd quarter worth $48,000. Tower Research Capital LLC TRC purchased a new stake in NextCure in the 2nd quarter worth $96,000. Morgan Stanley purchased a new stake in NextCure in the 2nd quarter worth $101,000. Strs Ohio lifted its stake in NextCure by 625.0% in the 3rd quarter. Strs Ohio now owns 5,800 shares of the company’s stock worth $178,000 after purchasing an additional 5,000 shares in the last quarter. Finally, Northern Trust Corp purchased a new stake in NextCure in the 2nd quarter worth $337,000. Institutional investors and hedge funds own 49.62% of the company’s stock.
NXTC stock traded down $0.31 during mid-day trading on Thursday, hitting $51.24. The company had a trading volume of 191,205 shares, compared to its average volume of 252,126. NextCure has a 12-month low of $13.86 and a 12-month high of $109.00. The company has a quick ratio of 15.00, a current ratio of 15.00 and a debt-to-equity ratio of 0.02. The company has a 50-day moving average price of $42.43 and a 200 day moving average price of $28.99.
NextCure (NASDAQ:NXTC) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.02). The business had revenue of $1.58 million for the quarter, compared to analyst estimates of $1.50 million. Analysts predict that NextCure will post -2.19 EPS for the current fiscal year.
NextCure Company Profile
There is no company description available for NextCure Inc
See Also: Should You Consider an Index Fund?
Receive News & Ratings for NextCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NextCure and related companies with MarketBeat.com's FREE daily email newsletter.